Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 63.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,355 shares of the biopharmaceutical company's stock after selling 33,458 shares during the period. Tealwood Asset Management Inc.'s holdings in Halozyme Therapeutics were worth $1,235,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Congress Asset Management Co. raised its position in Halozyme Therapeutics by 8.8% in the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock worth $136,088,000 after purchasing an additional 172,971 shares during the period. SeaCrest Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $213,000. Sugar Maple Asset Management LLC raised its holdings in shares of Halozyme Therapeutics by 32.1% in the first quarter. Sugar Maple Asset Management LLC now owns 10,300 shares of the biopharmaceutical company's stock worth $657,000 after buying an additional 2,500 shares during the period. Portside Wealth Group LLC boosted its holdings in Halozyme Therapeutics by 2.4% during the 1st quarter. Portside Wealth Group LLC now owns 9,317 shares of the biopharmaceutical company's stock valued at $595,000 after acquiring an additional 222 shares during the period. Finally, Juncture Wealth Strategies LLC boosted its holdings in Halozyme Therapeutics by 3.4% during the 1st quarter. Juncture Wealth Strategies LLC now owns 12,385 shares of the biopharmaceutical company's stock valued at $790,000 after acquiring an additional 407 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HALO. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Finally, Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $61.90.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the sale, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. The trade was a 1.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Down 1.1%

Shares of HALO traded down $0.61 during trading hours on Tuesday, hitting $53.77. The company had a trading volume of 1,718,114 shares, compared to its average volume of 1,635,610. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a market capitalization of $6.63 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The company's fifty day moving average price is $57.63 and its two-hundred day moving average price is $56.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same period in the previous year, the company posted $0.79 earnings per share. The firm's revenue was up 35.2% on a year-over-year basis. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.